الفهرس Only 14 pages are availabe for public view
 |  | from | 214 |  |  |
| | | from | 214 | | |
Abstract
Herpes simplex virus type 2 (HSV-2) is a one of the most prevalent worldwide sexually transmitted infection. HSV-2 causes recurrent genital ulcers, neonatal herpes, and also, increases the risk for human immunodeficiency virus (HIV) acquisition. Many HSV-2 vaccines have been tested in humans, but were not consistently effective. In the present work we tried to produce a model vaccine for HSV-2 formulated in different formulae as an attempt for development of an effective prophylactic and therapeutic HSV-2 vaccine. Beta propiolactone (BPL) as a virus inactivant was compared with the conventional formalin (F). Gold and silver nanoparticles were prepared with different concentrations as a vaccine adjuvants. Also, calcium phosphate nanoparticles and bovine serum albumin nanoparticles were used as vaccine adjuvants . They were compared with currently used aluminum phosphate gel (alum) microparticles